Polycomb repressive complex 2 inhibitors: emerging epigenetic modulators

Area of Science:

• Epigenetics
• Molecular Biology
• Drug Discovery

Background:

• Polycomb repressive complex 2 (PRC2) is crucial for histone methylation and gene silencing.
• PRC2 inhibition is a potential cancer therapy strategy.
• Several PRC2 inhibitors are in clinical trials.

Purpose of the Study:

• To summarize advances in PRC2 inhibitor drug discovery and development.
• To analyze chemotypes, activity, selectivity, and binding modes of PRC2 inhibitors.
• To provide insights for designing next-generation PRC2 inhibitors.

Main Methods:

• Review of current literature on PRC2 inhibitors.
• Analysis of inhibitor chemotypes, activity, selectivity, and binding modes.
• Focus on structure-based drug design principles.

Main Results:

• Detailed summary of various PRC2 inhibitor classes.
• Understanding of inhibitor binding modes.
• Identification of key features for PRC2 inhibition.

Conclusions:

• PRC2 inhibitors represent a promising therapeutic avenue for cancer.
• Structure-based drug design can guide the development of novel PRC2 inhibitors.
• Further research can optimize existing inhibitors and discover new ones.